SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Marksans Pharma informs about press release

05 Nov 2025 Evaluate
Marksans Pharma has informed that (Reuters: MARK.BO; Bloomberg: MRKS IN; NSE: MARKSANS; BSE: 524404) its wholly owned subsidiary Relonchem in UK has received Marketing Authorization for its product Exemestane 25mg film-coated tablets from UK MHRA.

The above information is a part of company’s filings submitted to BSE.  

Marksans Pharma Share Price

248.10 -1.50 (-0.60%)
16-Jun-2026 10:51 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1799.00
Dr. Reddys Lab 1282.00
Cipla 1387.65
Zydus Lifesciences 1085.85
Lupin 2268.85
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: